The use of stem cells in heart disease by Comparsi, Fernando Pflug et al.
RIALA6/1130
Rev Inst Adolfo Lutz, 66(3): 213-224, 2007
Fernando P. COMPARSI1, Sandrine C. WAGNER2, Patricia PRANKE1,3*
*Endereço para correspondência: Laboratório de Hematologia e Células-tronco, Faculdade de Farmácia , Universidade
Federal do Rio Grande do Sul (UFRGS). Av. Ipiranga n. 2752 Porto Alegre, RS, Brazil, Zip code: 90160-000 Tel. +55 51
3308-5257 or +55 51 3308 5275 Fax.+55 51 3308-5437. E-mail: patriciapranke@ufrgs.br
1. Faculdade de Farmácia, UFRGS, Porto Alegre, Brazil.
2. Curso de Biomedicina, Centro Universitário Feevale, Novo Hamburgo, Brazil.
3. Programa de Pós-graduação em Neurociências, UFRGS, Porto Alegre, Brazil.
Recebido: 27/08/2007 – Aceito para publicação: 28/12/2007
ABSTRACT
Stem cells are undifferentiated cells that are capable of both self-renewal and giving rise to several cell
types. Cardiovascular disease is the most important cause of death in western society and, in spite of
therapeutic advances in traditional medicine, it has not been possible to recover the original cardiac
function. Similarly, Chagas´ disease is an important cause of heart failure in Latin America. The
differentiation capacity of stem cells makes them an important source of cells for the regeneration of
cardiac tissue. Research using animal models of myocardial infarction has shown promising results for
the use of stem cells in heart disease therapy. Recent clinical trials have shown the safety and benefit of
therapy with stem cells in cardiac regeneration. Research in this field is still in the early stages and needs
to be consolidated to permit wider use of stem cells in clinical medicine. Nevertheless, cell therapy has
been shown to have potential as a new approach in the treatment of heart disease, which takes the lives of
millions people around the world.
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RESUMO
As células-tronco são células indiferenciadas capazes de auto-renovação e de originar diversos tipos
celulares. A doença cardiovascular é a causa mais importante de morte na sociedade ocidental e, apesar
dos avanços terapêuticos da medicina tradicional, não tem sido possível recuperar a função cardíaca
original. A doença de Chagas é também uma importante causa de insuficiência cardíaca na América
Latina. A capacidade de diferenciação das células-tronco faz dessas uma importante fonte de células
para a regeneração do tecido cardíaco. As pesquisas utilizando modelos animais com infarto do miocárdio
têm mostrado resultados promissores através do uso das células-tronco para a terapia das doenças
cardíacas. Recentes ensaios clínicos têm comprovado a segurança e os benefícios da terapia com células-
tronco na regeneração cardíaca. No entanto, as pesquisas nesse campo ainda estão em estágios iniciais e
necessitam ser consolidadas para permitir uma ampla utilização das células-tronco na medicina. Além
disso, a terapia celular tem mostrado grande potencial como uma nova abordagem terapêutica para o
tratamento das doenças cardíacas, as quais são responsáveis por tirar a vida de milhões de pessoas ao
redor do mundo.
Palavras-chave. células-tronco, infarto do miocárdio, doença de Chagas, terapia celular, regeneração
cardíaca.
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INTRODUCTION
Stem cells (SCs) are undifferentiated cells with a high
proliferation capacity. SCs are capable of self-renewal, which
is the ability to divide while remaining undifferentiated, thus
maintaining a permanent pool of cells. They also have the ability
to differentiate into a number of different cell types, given the
appropriate stimuli1.
Many researchers classify SCs according to their
differentiation capacity, which can be totipotent, pluripotent
and multipotent. In the fertilized egg, until about the third
day, all the cells are considered totipotent SCs, which mean
that these cells have the capacity to give rise to any one of
the approximately 217 cells types of the human organism
and the extraembryonic tissues. Pluripotent SCs give rise
to all the more than 200 cell types, derived from the three
embryonic germ layers (endoderm, mesoderm and
ectoderm), but not the extraembryonic tissues. The capacity
of multipotent SCs is limited to giving rise to the cells of a
specific tissue or organ, such as those of the hematopoietic
system, neurological system, liver, among others1,2,3.
Plasticity is the capacity of SCs to give rise to cell types
other than those that gave rise to them. This plasticity means
that SCs have a promising therapeutic role.
Stem cells are divided into two large groups,
according to their origin: Embryonic Stem Cells (ESCs)
and Adult stem cells (ASCs). ESCs are totipotent or
pluripotent. Generally, in human beings ESCs are obtained
in the period until the blastocyst phase, which corresponds
to approximately 150-200 cells, developed by the fifth or
sixth day following fertilization1,2. In the blastocyst phase,
the cells are considered pluripotent.
These cells also have a great capacity for self-
renewal ,  prol i ferat ing in cul ture and remaining
undifferentiated for an undetermined period. Moreover,
they are clonable, that is, they have the capacity to give
rise to genetically identical cell colonies. ASCs, found in
the formed individual, are also capable of self-renewal and
differentiation. Several studies have shown that some kinds
of ASCs have more plasticity than previously believed1,2.
Examples of these are Mesenchymal Stem Cells (MSCs)
and Multipotent Adult Progenitor Cells (MAPCs) which,
it has been suggested, have a similar degree of plasticity
to pluripotent ESCs.
Several  s tudies  have reported cases of
transdifferentiation, in which ASCs from one tissue type
have given rise to mature cells of a different kind. ASCs
from bone marrow (BM), which originates from the
mesoderm, can give rise to skeletal muscle cells, derived
from the mesoderm, neurons, derived from the ectoderm
and hepatocytes, derived from the endoderm. Research has
shown that SCs can acquire the phenotype of other cells
by spontaneous cellular fusion3. When Mononuclear Cells
(MNCs) from BM or neural stem cells were cultivated
together with ESCs, they adopted the phenotype and
plasticity of the latter through spontaneous cellular fusion.
Recent clinical trials in cardiac therapy have demonstrated
this. Among the different cell types that can be formed are
cardiomyocytes, smooth muscle cells and vascular
endothelial cells. The replacement of these cells permits a
new approach to the treatment of cardiovascular disease,
with marked advantages over conventional therapies4.
The aim of this paper is to discuss cell therapy as a novel
treatment for heart disease, to be considered as another option
which can be combined with conventional therapies to achieve
greater survival rates and better quality of life for patients with
such morbid and debilitating diseases. We review recent
research on the use of stem cells for cardiac regeneration,
including in vitro studies, animal experimentation and recent
clinical trials, which evaluate safety and feasibility of cell
therapy in the treatment of heart disease. These have been
carried out around the world and in Brazil, which has stood out
in this pioneering field, particularly with reference to Chagas´
disease (ChD). These studies will support greater future efforts
for research in this area and larger, more controlled clinical
trials to more precisely determine the benefits of cell therapy
in heart disease.
CARDIOVASCULAR DISEASES
Congestive heart failure affects 5 million people in
the United States of America with 400,000 new cases per
year. Cardiac and circulatory problems represent the main
cause  of  death   and  invalidity  in  the  United   States.
According to data from the Brazilian Health Ministry,
cardiovascular diseases constitute the most significant cause
of death throughout Brazil5. In 2001, cardiovascular diseases
were responsible for approximately 1.2 million admissions
to the Public Heath System, and 260 thousand deaths6.
Irreversible damage occurs early in the course of
myocardial  infarct ion (MI),  and the number of
cardiomyocytes lost is a major determinant in post-MI
cardiac function and prognosis. The limited regenerative
capacity of the heart results in the inability of the
cardiomyocytes to re-enter in the cellular cycle and
proliferate4.
Infection by Trypanosoma cruzi causes American
trypanosomiasis, or Chagas´ disease, which affects 16 to
18 million people, mostly in Latin America, 6 million of
which are in Brazil7. Approximately 30% of these patients
suffer a progressive destruction of the myocardium causing
chronic chagasic cardiomyopathy8 for which there is no
cure. Thus, ChD remains a significant cause of morbidity
and mortality in the most affected regions9. Chronic
Chagasic Cardiomyopathy (CChC) may lead to heart
enlargement and arrhythmia, causing cardiac dysfunction
and death8.
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CARDIAC REGENERATION
During embryogenesis and the beginning of post-natal
life, cardiomyocytes proliferate extensively. However, some
months later, the cardiomyocytes become terminally
differentiated. Adult ventricular cardiomyocytes are refractory
to cell cycle re-entry for reasons that include the lack of
telomerase activity10. These observations have led to the widely
held belief that the heart is incapable of regeneration.
Nevertheless, studies have shown that cardiomyocytes
are not only capable of dividing, but also that this capacity is
increased about ten-fold in severe heart failure. Cases where
male patients receive a heart from a female donor offer a unique
opportunity to investigate whether primitive cells migrate from
receptor to the transplanted organ and whether such cells remain
in the donated heart12. Quaini and colleagues11 used the presence
of the Y chromosome in cardiac cells of such patients to
determine that the cells were originally from the receptor. They
reported that 18% of the myocytes, 20% of the coronary arteries
and 14% of the capillaries were of male origin, and were formed
from the cells of the receptor in the post-transplant period.
Glaser and colleagues12 employed the same kind of sex-
mismatched heart transplants in order to investigate the
migration of receptor cells to transplanted heart. They observed
that, on average, 7.5% of the smooth muscle cells originated
from the receptor, but no myocytes of male origin were found.
At the same time, Müller and colleagues13 reported an average
of 0.16%, while Laflamme and colleagues14 found an average
of only 0.04% of cardiomyocytes from the receptor in
transplanted hearts.
The great disparity between these research findings, and
specially the non-confirmation, by other authors, of the notable
results obtained by Quaini and colleagues11, have generated
intense debate on the methods used and, principally, on the
criteria employed in interpreting the results.
Others factors, such as the shorter time interval between
the heart transplant and tissue analysis and, consequently, the
higher levels of infiltration by inflammatory cells into the
cardiac tissue, may be responsible for the high levels of
chimerism reported by Quaini and colleagues11. However, if
confirmed, these results would lead to a paradigm shift from
the accepted dogma that the heart is incapable of regeneration,
to one in which stem cells from the host may be recruited to
regenerate significant areas of the human heart15.
Even if the potential of the heart to regenerate is not as
great as that suggested by Quaini and colleagues11, proving to
be more limited, as indicated by the results reported by Müller
and colleagues13 and Laflamme and colleagues14, precedents
are opened for both the study and clinical use of the stimulation
of this intrinsic regenerative capacity of the heart in the
treatment of heart disease.
Recently, Oh and colleagues16, using cardiac progenitor
cells obtained from the myocardium of adult mice, have offered
an explanation for myocyte regeneration. These cells, when
injected into the jugular vein of infarcted mice, migrated to the
heart, and after two weeks, acquired the phenotype of myocyte,
by fusion and differentiation in similar proportions.
A recent interesting finding is that following acute MI,
there was a naturally occurring significant increase in the levels
of CD34+ progenitor cells in the peripheral blood, which peaked
between 24 and 48 hours after the first symptoms appeared
and gradually returned to normal values after 7 to 60 days17
CD34 is well known as a hematopoietic stem cell (HSC) marker.
The mobilization of CD34+ and endothelial progenitor
cells (EPCs) was observed in early stages of chronic heart
failure, together with a reduction in circulation levels of these
cells in advanced stages of the disease18. In patients with
coronary arterial disease, the level of circulating endothelial
progenitor cells is inversely related to the cardiovascular risk.
Studies showed that the patients with lower levels of circulating
CD34+ and KDR+ (kinase domain receptor) cells presented
higher frequency of important cardiovascular events during the
12 month period in which they were followed19.
Besides EPCs and HPCs, other subpopulations of cells
from the bone marrow, such as cardiac progenitor cells, have
been shown to be mobilized following damage to the
myocardium17,20. Increased plasma and tissue levels of vascular
endothelial growth factor (VEGF) have also been detected
after infarction, as well as the tissue levels of stromal derived
growth factor-1 (SDF-1), hepatocyte growth factor (HGF) and
leukemia inhibitory factor (LIF), in the damaged region of
the heart17.
These results suggest the existence of cardiac progenitor
cells in bone marrow that can be mobilized to the peripheral
blood following acute MI and attracted to the heart by the
release of chemotactic factors, where they repair the lesion.
It is important to highlight that the proliferation
mechanisms of cardiac cells following a trauma such as MI are
not capable of regenerating the heart and restoring original
cardiac function4,16.
Given this, the development of new therapeutic
approaches that permit the regeneration of lost cardiac tissue
is extremely important and stem cell therapy has a vital role
to play1.
RESEARCH INVOLVING STEM CELLS IN THE
REPAIR OF CARDIAC TISSUE
The use of autologous SC in the tissue engineering for
cardiovascular diseases is promising due to the capacity of self-
renewal, high proliferation and differentiation rate in specialized
progenitor cells21.
Several studies aimed at assessing the potential for the
use of stem cells in the repair of cardiac tissue have been carried
out. This approach has great advantages over heart transplant,
especially given the scarcity of available heart donors to meet
current transplant needs1.
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ANIMAL EXPERIMENTATION
In order to verify the feasibility, safety and beneficial
effects of stem cell transplantation for the treatment of heart
disease, especially MI, experiments with animal models have
been performed, inducing infarction in rats and mice. This is
achieved by the occlusion of the coronary artery which leads
to infarction of the cardiac region irrigated by that artery1.
Orlic and colleagues22 isolated lin- c-kit+ cells from
mouse BM, and injected them into the viable myocardium
adjacent to the infarcted area, some hours after the arterial
occlusion. Nine days after the transplant, 68% of the infarcted
area had been replaced by newly formed myocardium. The
developing tissue included vascular structures, proliferating
myocytes, and expressed markers of cardiac cells in
development. The expression of connexin 43, a protein
responsible for intercellular connection and electrical coupling
between myocytes, which is essential for the functional
integration of heart muscle cells was also seen23. Of even
greater significance was the improvement in the systolic and
diastolic pressure when compared with mice that did not
receive lin- c-kit+ cells following infarction. These data show
that the tissue formed from the transplanted cells had a positive
impact on cardiac function22. However, direct injection into
the heart, through thoracotomy, besides being technically
difficult in mice, is highly invasive, resulting in high mortality
and low grafting rates.
Therefore, Orlic and colleagues24 checked the effects of
the mobilization of BM cells through the injection of
granulocyte colony stimulating factor (G-CSF) and Stem Cell
Factor (SCF) in infarcted mice.
Granulocyte-colony stimulating factor (G-CSF) is a
hematopoietic growth factor which promotes proliferation and
differentiation of neutrophil progenitors and also has
immunomodulatory properties. G-CSF promotes the
mobilization of stem and progenitor cells from bone marrow
to the infarcted heart after acute MI. While there is controversy
regarding the capacity of mobilized stem cells to differentiate
into cardiomyocytes, the angiogenesis induced by G-CSF is a
known effect in the infarcted heart25.
Although some studies show that G-CSF can act directly
on cardiomyocytes25,26 promoting their survival after acute MI
and inducing the regeneration of myocardium in mice, the
mechanisms by which these benefits occur are not completely
known yet. G-CSF may induce the release of anti-apoptotic
proteins and inhibit the apoptosis of cardiomyocytes in the
infarcted heart. Furthermore, it seems to reduce the apoptosis
of endothelial cells, increasing the vascularization of the
infarcted heart, protecting it against ischemia26.
The results were encouraging, showing considerable
increase in the survival of treated mice when compared to the
control group: 85% to 35%, 6 days after the infarction, and
73% to only 17% after 27 days, respectively. It was seen that
repair had only occurred in the treated group, with the reduction
of the infarcted area from 64% to 39%, with the formation of
new myocytes. These cells expressed desmin, nestin, α-
sarcomeric actin, cardiac myosin and connexin 43, which are
heart cell development and integration markers. The
myocardium in formation occupied 76 ± 11% of the infarcted
area and consisted of myocytes, endothelial and smooth muscle
cells in proliferation. The ejection fraction was 48, 62, and 114%
greater in treated than in untreated mice, at 9, 16, and 26 days
following coronary occlusion, respectively. These results
demonstrated that this non-invasive protocol was well tolerated
by the recipient mice, and that autologous circulatory stem cells
migrate to the damaged region of the ischemic heart and give
rise to new cardiomyocytes and blood vessels, and so restore,
at least partially, heart function24.
Embryonic stem cells have the distinct potential for
tissue regeneration, including cardiac repair27 and they are
promising for cardiac repair28. Human ESCs can give rise to
cardiomyocytes in vitro29 and ESC-derived cardiomyocytes are
viable human heart cells that can functionally integrate with
the recipient organ after transplantation30. Cai and colleagues31
showed that transplantation of ESC-derived cardiomyocytes
improved cardiac function in infarcted rat hearts.
Min and colleagues32 induced MI in rats and used ESCs
from mice, cultivated for 7 to 8 days, permitting their
differentiation. For the transplant, cells previously transfected
with green fluorescent protein (GFP) were used. The cells were
injected into two points adjacent to the ischemic region, and
one point within the infarcted region, 30 minutes after infarction.
Six weeks after the infarction, the animals that received the
ESCs showed significant improvement in left ventricular
function, when compared with rats that received cell-free culture
medium (control). Considerable improvement was also seen in
the ventricular contraction of the group transplanted with ESCs.
The presence of GFP positive cells in the left ventricle shows
that the implanted ESCs not only survived in the damaged
myocardium, but also differentiated into mature cardiomyocytes
6 weeks after transplant.
The ability of cardiac-specified human ESCs to
differentiate along the cardiomyogenic pathway following
transplantation into infarcted myocardium raises the hope that
these cells might become effective candidates for myocardial
regeneration29. However, it is known that undifferentiated
mouse ESCs can formed teratomas in infarcted hearts,
indicating injury-related signals did not direct cardiac
differentiation28.  Their propensity for multilineage
differentiation carries, however, the liability of neoplastic
growth, impeding therapeutic application27. On the other hand,
no teratoma was observed in hearts or any other organ of the
body in studies from Tomescot and colleagues29, when they
studied the differentiation in vivo of cardiac committed human
embryonic stem cells in postmyocardial infarcted rats29. Behfar
and colleagues27 showed that cardiopoietic programming
established a strategy to hone stem cell pluripotency, offering
a tumor-resistant approach for regeneration.
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These controversial results show that the use of embryonic
stem cells in patients needs to be more studied before its
therapeutic application.
In a study using human peripheral blood MNCs, these
cells were expanded in culture medium prepared for endothelial
progenitor cells (EPCs) for 7 days. Infarction was induced in
rats and after 3 hours 106 EPCs were injected intravenously. After
28 days, the rats that received the cells exhibited lower left
ventricle systolic and diastolic volumes, as well as greater cardiac
contractility than rats from the control group. The increase in the
neovascularization produced by EPCs resulted in a reduction in
ventricular dilatation and maintenance of cardiac performance
after myocardial ischemia in rats33.
In a study carried out by Yeh and colleagues34, infarction
was induced in immunodeficient mice and 2.5 x 106 CD34+ cells
from human peripheral blood were transplanted by infusion into
the caudal vein. The infarcted area, but not the healthy portion
of the heart, presented human cardiomyocyte-like cells that
expressed HLA-ABC and cardiac protein (troponin T). Blood
vessels in the infarcted region were also found to contain cells
positive for HLA and smooth muscle α-actin or HLA and VE-
cadherin, demonstrating that human CD34+ transdifferentiated
into smooth muscle and endothelial cells in the damaged tissue.
These events were not observed in mice that received only cells,
in the absence of infarction.
In another study, BM cells were mobilized by the
administration G-CSF in humans and then collected from the
peripheral blood by means of leukapheresis. Forty-eight hours
after infarction induced by occlusion of the left anterior
descending coronary artery in athymic rats, 2 x 106 human CD34+
cells were injected into the caudal vein. After 2 weeks, a
significant increase in microvascular density was seen in the
infarcted area (with vessels constituted of human cells), and in
the peri-infarcted region (with vessels containing rodent cells).
Moreover, the rats that received human cells showed significant
improvement in cardiac function, with relative increase of 22%
and 34%, relative to post-infarction values, at 2 and 15 weeks,
respectively. Furthermore, the frequency of apoptotic myocytes
was 6 times lower in the treated group than in the control group35.
The use of an alternative source of stem cells, from the
mononuclear fraction of umbilical cord blood (UCB) has been
studied in several diseases, including cardiac diseases. Recent
studies in mice have shown that in 50% of animals with
myocardial infarction the mononuclear cells (MNCs) from UCB
migrate to the heart after the intravenous injection. Again in mice,
when cells from UCB or BM enriched with CD133, a marker of
EPCs, were directly injected in the infarcted area of myocardium,
an improvement in the contractility of myocardium and in the
neovascularization of ischemic myocardium was observed36.
In an animal model of chronic ischemia in dogs, an
increase in the vascularization and an improvement in the cardiac
function were demonstrated after the implant of mesenchymal
stem cells (MSCs). These cells differentiated into smooth muscle
and endothelial cells, suggesting the formation of new vessels.
Amado and colleagues37 performed an allogeneic transplant of
MSCs in pigs and achieved significant improvement in the cardiac
function. On the other hand, Deten38 and Balsam39 and their
colleagues, with the mobilization and intravenous injection of
bone marrow cells, did not detect any sign of myocardium
regeneration in the heart of infarcted mice. 
These animal experiments have demonstrated the great
potential of stem cells obtained from different sources, in the
regeneration of cardiac tissue, through the revascularization of
damaged tissue, and differentiation into cardiac cells, which leads
to tissue restoration and the recovery of cardiac function. The
cell types, animals, means of administration and main results of
the presented studies are summarized in Table 1.
CLINICAL TRIALS
A number of successful studies in the application of stem
cell therapy in heart disease using animal models have
stimulated ongoing clinical trials1.
Perin and colleagues40 performed the autologous
transplant of MNCs from BM in 14 patients with severe chronic
ischemic heart failure. The control group consisted of 7 patients
who received only conventional therapy. A NOGA catheter was
used to administer 15 transendocardial injections delivering a
total of 2 to 3 x 107 cells per patient. The population of cells
injected contained 2.4 ± 1.3% of CD45dim CD34+ cells. The
patients were evaluated two months after the transplant, and
presented significant improvement when compared to the
evaluation made prior to the procedure and the control group.
The patients that received the transplant showed improvement
in heart condition, with fewer symptoms of angina and greater
exercise capacity. Improvement was observed in the ejection
fraction measured by echocardiogram and the final systolic
volume, as well as the cardiac tissue perfusion (a 73% reduction
in the total reversible defect). The transplanted group was re-
evaluated after 4 months, and angiography showed significant
improvement in ejection fraction and end systolic volume.
Moreover, improvement in mechanical function was seen in
the cell injection sites. This research demonstrated the safety
and efficacy of performing autologous transendocardial
transplant of MNCs from BM.
Strauer and colleagues41 were the first to perform the
intracoronary autologous transplant MNCs from BM in patient
with acute MI. Ten (10) patients received injections of around
2 x 107 MNCs during angioplasty while a control group of 10
patients had only angioplasty. Three months after the procedure
the patients that received cell therapy presented a significant
reduction in the infarcted area (from 30 ± 13% to 12 ± 7%), a
significant increase in motility in the affected region, as well as
reduction in the end systolic volume.
 In a study using AC133+cells selected from the BM of
patients with MI, a group of 6 patients received 1,5 X 106 cells
directly into the peri-infarcted area, together with coronary
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revascularization. This resulted in an increase in global
ventricular function and perfusion of the infarcted region 3 to
9 months after the procedure. AC133+ cells include a sub-
population of CD34- cells, have great potential of inducing
angiogenesis, and may be responsible for the increased
perfusion in the cardiac tissue, though the affect of
revascularization surgery cannot be ignored42.
Tse and colleagues43 reported a significant decrease in
angina episodes and the use of nitrates in 8 patients with ischemic
heart disease, 3 months after autologous transendocardial
transplant of MNCs. NOGA system was used to electronically
map the hearts of the patients and inject the cells into the ischemic
area of the myocardium. A significant improvement in the cardiac
contraction was noted in the patients.
Menasché group pioneered the use of skeletal myoblasts,
with first implant of autologous myoblasts into a patient
suffering from infarction. They followed up 10 patients
submitted to the same treatment and noted improved cardiac
function and increased ejection fraction. On the other hand,
ventricular arrhythmia was seen in 4 patients, which has led to
concern regarding the safety of skeletal myoblast transplant44.
The presence of arrhythmia may be linked to the lack of a
functional integration capacity in the newly formed tissue. This
incapacity is due to the absence of electrical coupling between
the new muscle cells and the cardiomyocytes, which was
confirmed by the absence of connexin 43 and cadherin
expression in the grafted cells45.
Schächinger and colleagues46 performed intracoronary
autologous transplant of progenitor cells in 59 patients with
acute MI. Twenty nine patients received MNCs from BM and
the other 30 received peripheral blood cells expanded in vitro
and with characteristics of endothelial progenitors cells. In the
preliminary evaluation of the first 20 patients, the two groups
(9 and patients, respectively) obtained comparable results in
the follow-up four months after the procedure. Both showed
significant improvement in ejection fraction, end systolic
volume, cardiac contraction and perfusion, when compared to
baseline values and the control group of 11 patients that received
only conventional treatment47. After 12 months follow-up of
all the patients an even greater improvement was noted in the
ejection fraction, along with a decrease in end systolic volume
and maintenance of end diastolic volume, demonstrating a
favorable ventricular remodeling and no infarction spread46.
Based on the observation that progenitor cells derived from
both BM and peripheral blood increased the neovascularization
in ischemic tissue33,35, it has been suggested that improvement
in ventricular function following experimental induction of a
MI is due to the stimulation of angiogenesis. Thus, the
Table 1. Experiments in animal models using SCs in cardiac regeneration.
SCs: stem cells; BM: bone marrow; G-CSF: granulocyte colony stimulating factor; SCF: Stem Cell Factor; ESCs: Embryonic Stem Cells; PB: Peripheral
Blood; EPCs: endothelial progenitor cells; My: myocytes; AMI: acute myocardial infarction. SMCs: smooth muscle cells; MNCs: mononuclear cells;
UCB: umbilical cord blood.
Cells
lin- c-kit+ from BM from
mice
Cells mobilized from BM





CD34+ from human PB
CD34+ from human PB
mobilized by G-CSF
MNCs fromUCB
Selected CD133 cells from
UCB or BM
Animal/Route of Administration
Border of infarcted area in mice
Infarcted mice








Intravenously in infarcted mice
Injection in infarcted area in
mice
Main Results
1) Regeneration of 68% of the infarcted
region; 2) New My;3) cardiac function
improvement
1)Increased survival; 2) New
My;3)cardiac function improvement
1) New My;2) cardiac function
improvement
1) Increased vasculogenesis of ischemic
tissue; 2) cardiac function improvement
1) New My, SMCs and vascular
endothelial cells
1) Vasculogenesis in the infarcted area
and angiogenesis in the periphery; 2)
cardiac function improvement
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enhanced blood flow makes it possible to prevent myocardial
remodeling and limits myocytic apoptosis, reduces collagen
deposition and scar formation33,35,47. While arrhythmia has
appeared to be an important limitation to the use of SCs
derived from skeletal myoblasts44, in this study none of the
transplanted patients presented arrhythmia, demonstrating the
safety of the procedure46.
Another study used SCs from peripheral blood mobilized
by G-CSF for the autologous transplant during heart by-pass
surgery. The stem cells were infused into the coronary artery or
injected into non-fibrotic areas of the myocardium, adjacent to
the infarcted region. There was improvement in the clinical
conditions of the 5 patients, mainly in those that had recently
suffered infarction. However, further research will be necessary
to confirm the results48.
Fernández-Avilés and colleagues transplanted
autologous MNCs from BM in 5 patients with acute MI due to
stenosis of the left anterior descending coronary artery. A
catheter was used to infuse around 5 x 107 cells into the affected
artery, 10 –15 days after infarction. Six months after the
transplant, an improvement was noted, though not significant,
in the ejection fraction and final diastolic and systolic volumes.
The same authors later published the results of a study
containing 20 patients that showed significant improvement in
ejection fraction and end systolic volume after 6 months,
reflecting improved cardiac contraction, while in the control
group (13 patients) no significant improvement was seen49.
A randomized clinical trial was carried out with 60
patients that had suffered acute MI and percutaneous coronary
intervention. A catheter was used to transplant 2.5 x 109
nucleated cells from BM (containing approximately 107 CD34+
cells) into the coronary artery linked to the infarction. The
patients were followed-up for 5 to 6 months after the transplant
and magnetic resonance was used to determine the left-
ventricular ejection fraction. The group of 30 patients that
received cell therapy presented a significant elevation of 6.7 ±
6.5% in LVEF, while in the control group the elevation in LVEF
was only 0.7 ± 8.1%. Moreover, the absence of the pro-
arrhythmia effect in the transplanted patients demonstrates the
safety of cell therapy in cardiac regeneration following MI50.
Ince and colleagues51 studied the effect of mobilization
of CD34+ cells from BM in patients suffering from acute MI.
Fifteen patients received subcutaneous injection of G-CSF
for 6 days and traditional treatment, while the control group
received only the conventional treatment. During the treatment
with G-CSF, the level of circulating CD34+ cells increased 20
times, while they remained constant in the control group. In
evaluations made 4 and 12 mounts after the treatment, the
patients who received G-CSF showed significant improvement
in cardiac motility, ejection fraction and cardiac geometry,
when compared to the control group. Moreover, no adverse
effects were observed, including electrical instability or
accelerated restenosis.
In a randomized double blind study with 114 patients
with acute MI, 56 patients received daily subcutaneous doses
of G-CSF for five days, while 58 patients received placebo,
during the same period. Increases in circulating CD34+ cells,
as well as in the level of granulocytes, monocytes and
lymphocytes were observed in the patients who received G-
CSF. However, the study showed that although the treatment
produced a significant mobilization of stem cells, the use of
G-CSF did not change the size of the infarction or the left
ventricular function after the acute MI in patients. On the other
hand, in contrast with other studies, the risk of coronary
restenosis did not increase and other collateral effects were
not observed52.
In a study carried out by a group of Brazilian
researchers, 9 patients received cell therapy for the treatment
of heart failure due to ChD, hypertension and unknown origin
(idiopathic dilated cardiopathy). Two patients received GM-
CSF to mobilize SCs from BM that were then collected in the
peripheral blood for leukapheresis and administered via
intracoronary method using a catheter. In the other 7 patients,
the cells were merely mobilized to the peripheral blood by
the administration of GM-SCF, with the aim of observing
whether the cells migrate to the damaged cardiac tissue to
induce repair. The preliminary results showed there was
improvement in the condition of the first patients that received
the treatment, with improved ejection fraction and endurance
during exercise. Three of these patients have now left the heart
transplant waiting list9.
Since October 2003, in Rio Grande do Sul, stem cell
transplant has been performed on 7 patients with heart failure,
and the patients are responding well to the treatment53. In another
study, published in 2004, Sant’Anna and colleagues53 showed
the results of SCT in 7 patients with cardiac failure, who
responded well to the treatment.
Tura and colleagues54 have designed clinical trials to
test for the efficacy of autologous bone marrow derived
mononuclear cell therapies in four different cardiopathies: acute
and chronic ischemic heart disease, and Chagasic and dilated
cardiomyopathy. In each trial 300 patients will be enrolled and
receive optimized therapy for their specific condition.
Additionally, half of the patients will receive the autologous
bone marrow cells while the other half will receive placebo.
Many phase I clinical trials using cell therapy for cardiac
diseases have already been performed. The few randomized
studies have yielded conflicting results, rendering necessary
larger well controlled trials to test for efficacy of cell therapies
in cardiopathies.
All the published clinical trials have involved
autologous transplants, that is, the patients own cells were
used, so avoiding the risk of rejection and the need for
immunosuppression, inherent in allogeneic transplants. The
cell types used, the administration method, the number of
patients and the types of heart disease are summarized in
Table 2.
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STEM CELLS IN CHAGAS´ DISEASE
The discovery of the pluripotential capacity of SCs from
BM, and with it, the emergence of new perspectives for the
treatment of, until then, incurable degenerative diseases, as well
as the promising results of the use of these cells in cardiac
regeneration22,40,50, has led to the study of the use of cell therapy
in the treatment of CChC.
A pioneering study in relation to ChD is being
undertaken by a group of researchers from different Brazilian
institutions, including Fiocruz from Bahia, a state with a high
incidence of this disease. It has recently been demonstrated
that BM cells injected intravenously into mice with chronic
ChD migrated to the heart and provoked a significant reduction
in the inflammatory infiltrates and in interstitial fibrosis,
characteristic properties of CChC. Beneficial effects were seen
within 6 months after transplant from BM. Massive apoptosis
of inflammatory cells in the myocardium was noted after the
therapy with BM cells. However, there was no increase in
parasitism, indicating that the marked reduction in cardiac
inflammation was not due to a generalized immunosuppression.
It was also found that a fraction of the cells expressed cardiac
myosin, but only in the hearts of chagasic mice, showing the
need for the presence of tissue damage to provoke the migration
of the cells and induce repair. Of particular importance is the
finding that cells obtained from the BM of both normal and
chagasic mice had comparable effects in inducing repair in the
chagasic heart. The results show that the transplant of cells
from BM is effective in the treatment of CChC and that the
autologous transplant of BM can be used as an efficient therapy
for patients afflicted by this pathology55.
Based on the experience obtained in research with the
transplant of SCs for ChD in mice and the encouraging results
achieved in these studies55, a surgical protocol has been
applied, since July 2003, with the aim of improving the quality
of life patients with ChD. Preliminary results have
demonstrated the success of the procedure in 5 patients56 that
received an intracoronary autologous injection of SCs from
BM via cardiac catheterism57. The aim is to extend the study
to more 25 patients56.
Table 2. Clinical trials using cellular therapy in patients with heart disease
Administration
Transendocardial guided by NOGA





Direct injection into border of infarcted region,
during by-pass surgery
Direct injection into infarcted Myc, during by-
pass surgery




Injection of  G-CSF
N: number of patients that received cell therapy / control group (when existent); MNCs: Mononuclear Cells; BM: Bone Marrow; PB: Peripheral Blood; G-







PB Expanded in vitro
AC133+ Cells from BM
Skeletal Myoblasts
PB mobilized by G-CSF
Nucleated cells from BM
PB mobilized by G-CSF
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DISCUSSION
Although experiments with animal models of infarction
have shown the differentiation of SCs from BM into
cardiomyocytes22, the extent to which this is reproducible in
humans is unknown. The confirmation of the presence of
cardiac cells from the host in the transplanted hearts supports
the differentiation of SCs into cardiomyocytes in vivo in the
human heart. However, the inconsistency of the results from
different research groups as hampered the attainment of more
solid conclusions.
It is also important to try to discover the action
mechanism of SCs. Transdifferentiation and cellular fusion have
both been suggested as the action mechanisms involved in the
tissue regeneration process induced by SCs. However, the low
frequency with which some studies have demonstrated these
events3 has led to suggestions that other mechanisms may be
involved. One such mechanism would be that the delivered SCs,
release growth factors at the damaged tissue, and assist the
“modulation” of the damaged environment. These factors may
stimulate the proliferation of resident or circulating SCs and
tissue regeneration. Much further research will be necessary to
improve our understanding of these and other, as yet unknown
action mechanisms of SCs.
Other studies with animals have indicated angiogenesis
in the ischemic tissue, induced by transplanted cells, as an
important mechanism in the recovery of cardiac function33,35.
The evidence to support this includes the reduction in the
occurrence of angina and increased myocardial perfusion,
without alteration to heart contraction, as confirmed by Tse
and colleagues43. Another important finding is the increase in
perfusion and cardiac contraction in viable but non-functional
regions of the myocardium that received BM derived SCs,
reported by Perin and colleagues40. The findings of Stamm and
colleagues42 also suggest that angiogenesis plays an important
role in the infarcted tissue leading to cardiac regeneration. The
group noted the increase in ventricular function and myocardial
perfusion in patients that received transplanted cells with high
angiogenic potential. Furthermore, Assmuss and colleagues47
demonstrated significant improvement in cardiac contraction
and perfusion in patients that received in vitro expanded EPCs,
derived from peripheral blood cells.
Although the results of clinical trials point to
angiogenesis as the main process responsible for cardiac
regeneration, the proliferation of cardiomyocytes and the
differentiation of progenitor cells, probably also play important
roles. However, the complete mechanism is far from being
understood. Perhaps, the increase in perfusion induced by
angiogenesis in the ischemic region facilitates improved
intrinsic regenerative capacity of the heart, through the increase
availability of oxygen and nutrients for cellular proliferation
and tissue regeneration.
Other questions, besides the mechanisms responsible
for the cardiac regeneration induced by SCs, regarding the use
of cell therapy in heart disease remain unanswered. An example
is the necessity or possibility of cell manipulation for the
purification of a specific population or in vitro differentiation
prior to transplant.
While different studies have used cells derived from
different sources, no conclusion has been reached on the cell
type best indicated for implant. A further point to be considered
is that of the best cell administration route. NOGA appeared to
be one of the more promising methods, as the transendocardial
injection can be guided by electromechanical mapping, allowing
the administration of cells into viable but non-functional regions
of the myocardium. Intracoronary infusion via catheter into the
artery responsible for the infarction, following its
desobstruction, is another strategy and permits the use of larger
volumes of cellular suspension and the contact of the cells with
all the affected tissue. Though these strategies are less invasive
than direct injection into the myocardium through thoracotomy
during by-pass surgery, and have been shown to be safer in the
clinical trials in which they have been employed, the need to
use NOGA has been debated. Attempts have been made to
substitute NOGA by other procedures, because of its invasive
nature and high cost.
Less invasive methods of SCs implant have shown
promising results. Nevertheless, perhaps cell implant itself may
not be necessary. Maybe the administration of cytokines, such
as G-SCF or SCF, which mobilize BM derived SCs to the
peripheral blood, is sufficient to ensure stem cell migration to
the damaged cardiac tissue. Alternatively these cells may be
collected from the peripheral blood after mobilization with
cytokines, and then implanted into the heart to increase their
concentration in the target tissue. Though such approaches
remove the need for cell aspiration from BM, they have been
less tested in animal experiments and clinical trials, and their
efficacy and safety have not yet been established.
Kang and colleagues58 found a high incidence of
restenosis in the infarcted artery in patients that received G-
CSF, despite cardiac function improvement. However, there
were few patients in the study sample, and the result has not
been confirmed by other research51.
Controversy remains regarding the results and
procedures employed in recent studies. Silva and colleagues59
demonstrated increased vascularity and improved cardiac
function in a canine chronic ischemia model, using
mesenchymal stem cells differentiated into smooth muscle cells
and endothelial cells. On the other hand, Deten and colleagues37
found no detectable signs of myocardial regeneration in
infarcted mouse heart with the mobilization or intravenous
injection of BM cells.
An important problem to be solved is that the
mobilization of BM derived cells to the peripheral blood takes
several days, and hence increases the time delay between
infarction and treatment. The early induction of angiogenesis
in the infarcted tissue and the consequent increase in perfusion
appear to inhibit late ventricular remodeling and the
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deterioration of the myocardium, thus preserving cardiac
function33,35,42,47. While tissue damage is an important factor for
the migration of SCs and their incorporation into the affected
tissue, the ideal time period for treatment initiation following
infarction remains to be established.
It is known that delivered factors from myocardium during
the inflammatory process play an important role in increasing
homing, migration and implantation of systematically infused
stem cells. Despite the controversy surrounding the capacity of
mobilized SC to differentiate into cardiomyocytes and the fact
that the effects of G-CSF on the advance of atherosclerosis are
not fully understood, the use of this growth factor seems to
represent a promising therapy for ischemic events25.
The CXCR4 molecule is a recently discovered marker
involved in the process of attraction of stem cells to the sites of
damaged tissue. When tissue is damaged, CD34+CXCR4+ cells
migrate to the site of the lesion, attracted by SDF-1 secretion,
the ligand of the CXCR4 receptor. Niches of SDF-1 are found
in the damaged organs and they are delivered during the tissue
damage. The organization of cellular niches is known to have a
key role in regulating normal stem cell differentiation and in
the regeneration of tissue. Thus, CXCR4+ cells are important
in the regeneration of damaged organs, showing the regenerative
capacity of stem cells60, such as HSC and MSC, which express
this marker on their cellular surface. Bone marrow and skeletal
muscle also contain a population of CXCR4 cells that express
specific genes for muscle progenitor cells and that can be
mobilized to peripheral blood20. These cells are attracted by
the SDF-1 delivered in the damaged area of the organ and they
can help in the repair of the infarcted heart17,20.
Clinical trials have included both patients suffering from
acute MI, and patients with chronic heart failure. Though it is
not yet possible to compare the results due to the low number
of studies and of patients, in both cases improvement has been
seen in patients. An important factor is that there are more
patients with chronic heart failure and their situation is more
severe, as frequently there is no option available other than
heart transplant. Clinical trials until now have included patient
follow-up of at most 12 months, and as yet it is not known
whether transplanted cells survive in the heart for longer periods,
nor for how long the beneficial effects will remain.
There is a need for continued research with animal
models as well as clinical trials to enhance our understanding
and facilitate the wider use of SCs in the treatment of heart
disease. Though, advances in stem cell therapy have broken
paradigms and shown it to be a promising treatment for the
regeneration of tissue, especially in the heart.
CONCLUSION
Stem cells have great potential in the regeneration of
cardiac tissue, through the formation of new myocytes,
endothelial and smooth muscle cells. The partial repair of the
infarcted heart, seen in several studies, suggests that transplanted
cells respond to signals from the damaged myocardium, that
provoke their migration, proliferation and differentiation within
and around the infarcted area. Of greater importance, is the
significant improvement observed in the clinical condition of
the patients submitted to SCs treatment. In the studies so far
performed, improvement has been reported in hemodynamics,
cardiac geometry, myocardium perfusion and contraction, and
endurance during exercises, as well as reduction in the
occurrence of angina. Moreover, the relative safety observed
in these studies encourages the performance of larger
randomized controlled studies, to better evaluate the potential
of cell therapy and disseminate its therapeutic use.
The treatment of the sick heart in patients with ChD by
cell therapy is particularly important in Brazil and Latin
America. The results obtained with cell therapy in animal models
of CChC and the recent implementation of a surgical protocol
for the autologous transplant of SCs in chagasic patients give
new hope to millions of people that suffer from ChD57.
Stem cell therapy therefore points to a promising future
for regenerative medicine, and has become a great hope in the
treatment of heart disease, adding to the therapeutic arsenal of
the clinician in the combat of diseases that represent such a
heavy burden for society.
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